Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer.

K Bixel,M Vetter,B Davidson, A Berchuck,D Cohn,L Copeland,J M Fowler,L Havrilesky,P S Lee,D M O'Malley,R Salani,F Valea,A Alvarez Secord,F Backes

GYNECOLOGIC ONCOLOGY（2020）

引用 7|浏览17

暂无评分

摘要

•Intraperitoneal (IP) chemotherapy after neoadjuvant chemotherapy (NACT)/interval tumor reductive surgery (TRS) improved PFS.•Overall survival did not differ by route of administration of chemotherapy following NACT and interval TRS.•There were no significant differences in grade 3 or 4 toxicities for women receiving IP or intravenous (IV) chemotherapy.

查看译文

关键词

Neoadjuvant chemotherapy,Intraperitoneal chemotherapy,Ovarian cancer

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要